138907-69-4 Usage
Uses
Used in Pharmaceutical Industry:
ETHYL 5-AMINO-1-(2,5-DIFLUOROPHENYL)PYRAZOLE-4-CARBOXYLATE is used as a key intermediate in the synthesis of new drugs and medications due to its unique chemical properties and structural features. Its potential applications can be further explored through ongoing research and testing, which may lead to the discovery of novel therapeutic agents.
In the development of new pharmaceuticals, ETHYL 5-AMINO-1-(2,5-DIFLUOROPHENYL)PYRAZOLE-4-CARBOXYLATE may serve as a building block for creating molecules with specific biological activities, such as targeting particular receptors or enzymes involved in disease processes. The presence of the amino group, pyrazole ring, and difluorophenyl group can contribute to the compound's ability to interact with biological targets, potentially leading to the creation of effective treatments for various medical conditions.
Furthermore, the carboxylate ester functionality in ETHYL 5-AMINO-1-(2,5-DIFLUOROPHENYL)PYRAZOLE-4-CARBOXYLATE may also play a role in the compound's pharmacokinetic properties, such as solubility, stability, and bioavailability, which are crucial factors in drug development.
Overall, the diverse structural elements of ETHYL 5-AMINO-1-(2,5-DIFLUOROPHENYL)PYRAZOLE-4-CARBOXYLATE make it a promising candidate for pharmaceutical applications, with the potential to contribute to the advancement of new and improved therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 138907-69-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,9,0 and 7 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 138907-69:
(8*1)+(7*3)+(6*8)+(5*9)+(4*0)+(3*7)+(2*6)+(1*9)=164
164 % 10 = 4
So 138907-69-4 is a valid CAS Registry Number.
138907-69-4Relevant academic research and scientific papers
Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase
Wurz, Ryan P.,Pettus, Liping H.,Xu, Shimin,Henkle, Bradley,Sherman, Lisa,Plant, Matthew,Miner, Kent,McBride, Helen,Wong, Lu Min,Saris, Christiaan J.M.,Lee, Matthew R.,Chmait, Samer,Mohr, Christopher,Hsieh, Faye,Tasker, Andrew S.
scheme or table, p. 4724 - 4728 (2010/05/17)
A novel class of fused pyrazole-derived inhibitors of p38α mitogen-activated protein kinase (MAPK) is disclosed. These inhibitors were evaluated for their ability to inhibit the p38α enzyme, the secretion of TNFα in a LPS-challenged THP1 cell line and TNF
